Drug-eluting stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy

Michail I. Papafaklis, Yiannis S. Chatzizisis, Katerina K. Naka, George D. Giannoglou, Lampros K. Michalis

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Restenosis following stent implantation diminishes the procedure's efficacy influencing long-term clinical outcomes. Stent-based drug delivery emerged a decade ago as an effective means of reducing neointimal hyperplasia by providing localized pharmacotherapy during the acute phase of the stent-induced injury and the ensuing pathobiological mechanisms. However, drug-eluting stent (DES) restenosis may still occur especially when stents are used in complex anatomical and clinical scenarios. A DES consists of an intravascular metallic frame and carriers which allow controlled release of active pharmaceutical agents; all these components are critical in determining drug distribution locally and thus anti-restenotic efficacy. Furthermore, dynamic flow phenomena characterizing the vascular environment, and shear stress distribution, are greatly influenced by stent implantation and play a significant role in drug deposition and bioavailability within local vascular tissue. In this review, we discuss the performance of DES and the interaction of the different DES components with the hemodynamic milieu emphasizing on the inhibition of clinical restenosis.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalPharmacology and Therapeutics
Volume134
Issue number1
DOIs
StatePublished - Apr 1 2012

Fingerprint

Drug-Eluting Stents
Stents
Pharmacokinetics
Hemodynamics
Pharmaceutical Preparations
Blood Vessels
Biological Availability
Hyperplasia
Drug Liberation
Drug Therapy
Wounds and Injuries

Keywords

  • Drug release
  • Drug-eluting stent
  • In-stent restenosis
  • Percutaneous coronary intervention
  • Polymer coating
  • Shear stress

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug-eluting stent restenosis : Effect of drug type, release kinetics, hemodynamics and coating strategy. / Papafaklis, Michail I.; Chatzizisis, Yiannis S.; Naka, Katerina K.; Giannoglou, George D.; Michalis, Lampros K.

In: Pharmacology and Therapeutics, Vol. 134, No. 1, 01.04.2012, p. 43-53.

Research output: Contribution to journalReview article

Papafaklis, Michail I. ; Chatzizisis, Yiannis S. ; Naka, Katerina K. ; Giannoglou, George D. ; Michalis, Lampros K. / Drug-eluting stent restenosis : Effect of drug type, release kinetics, hemodynamics and coating strategy. In: Pharmacology and Therapeutics. 2012 ; Vol. 134, No. 1. pp. 43-53.
@article{a645662506d843a68ec8687b6227d0b9,
title = "Drug-eluting stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy",
abstract = "Restenosis following stent implantation diminishes the procedure's efficacy influencing long-term clinical outcomes. Stent-based drug delivery emerged a decade ago as an effective means of reducing neointimal hyperplasia by providing localized pharmacotherapy during the acute phase of the stent-induced injury and the ensuing pathobiological mechanisms. However, drug-eluting stent (DES) restenosis may still occur especially when stents are used in complex anatomical and clinical scenarios. A DES consists of an intravascular metallic frame and carriers which allow controlled release of active pharmaceutical agents; all these components are critical in determining drug distribution locally and thus anti-restenotic efficacy. Furthermore, dynamic flow phenomena characterizing the vascular environment, and shear stress distribution, are greatly influenced by stent implantation and play a significant role in drug deposition and bioavailability within local vascular tissue. In this review, we discuss the performance of DES and the interaction of the different DES components with the hemodynamic milieu emphasizing on the inhibition of clinical restenosis.",
keywords = "Drug release, Drug-eluting stent, In-stent restenosis, Percutaneous coronary intervention, Polymer coating, Shear stress",
author = "Papafaklis, {Michail I.} and Chatzizisis, {Yiannis S.} and Naka, {Katerina K.} and Giannoglou, {George D.} and Michalis, {Lampros K.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.pharmthera.2011.12.006",
language = "English (US)",
volume = "134",
pages = "43--53",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Drug-eluting stent restenosis

T2 - Effect of drug type, release kinetics, hemodynamics and coating strategy

AU - Papafaklis, Michail I.

AU - Chatzizisis, Yiannis S.

AU - Naka, Katerina K.

AU - Giannoglou, George D.

AU - Michalis, Lampros K.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Restenosis following stent implantation diminishes the procedure's efficacy influencing long-term clinical outcomes. Stent-based drug delivery emerged a decade ago as an effective means of reducing neointimal hyperplasia by providing localized pharmacotherapy during the acute phase of the stent-induced injury and the ensuing pathobiological mechanisms. However, drug-eluting stent (DES) restenosis may still occur especially when stents are used in complex anatomical and clinical scenarios. A DES consists of an intravascular metallic frame and carriers which allow controlled release of active pharmaceutical agents; all these components are critical in determining drug distribution locally and thus anti-restenotic efficacy. Furthermore, dynamic flow phenomena characterizing the vascular environment, and shear stress distribution, are greatly influenced by stent implantation and play a significant role in drug deposition and bioavailability within local vascular tissue. In this review, we discuss the performance of DES and the interaction of the different DES components with the hemodynamic milieu emphasizing on the inhibition of clinical restenosis.

AB - Restenosis following stent implantation diminishes the procedure's efficacy influencing long-term clinical outcomes. Stent-based drug delivery emerged a decade ago as an effective means of reducing neointimal hyperplasia by providing localized pharmacotherapy during the acute phase of the stent-induced injury and the ensuing pathobiological mechanisms. However, drug-eluting stent (DES) restenosis may still occur especially when stents are used in complex anatomical and clinical scenarios. A DES consists of an intravascular metallic frame and carriers which allow controlled release of active pharmaceutical agents; all these components are critical in determining drug distribution locally and thus anti-restenotic efficacy. Furthermore, dynamic flow phenomena characterizing the vascular environment, and shear stress distribution, are greatly influenced by stent implantation and play a significant role in drug deposition and bioavailability within local vascular tissue. In this review, we discuss the performance of DES and the interaction of the different DES components with the hemodynamic milieu emphasizing on the inhibition of clinical restenosis.

KW - Drug release

KW - Drug-eluting stent

KW - In-stent restenosis

KW - Percutaneous coronary intervention

KW - Polymer coating

KW - Shear stress

UR - http://www.scopus.com/inward/record.url?scp=84857362749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857362749&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2011.12.006

DO - 10.1016/j.pharmthera.2011.12.006

M3 - Review article

C2 - 22212618

AN - SCOPUS:84857362749

VL - 134

SP - 43

EP - 53

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -